je.st
news
Tag: patients
Health technology puts patients first
2014-09-23 01:00:34| BBC News | Business | UK Edition
The tech making life a little easier for patients
Tags: health
technology
patients
puts
Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
2014-09-17 15:31:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Omarigliptin significantly reduced HbA1c levels compared to placebo WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Mercks once-daily DPP-4 inhibitor JANUVIA (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Language: English Contact: MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (267) 305-1221 or +1 (310) 617-1067orInvestors:Justin Holko, +1 (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Expert lectures doctors about hidden dangers of wireless radiation from patients' cell phones, Wifi
2014-09-11 16:49:51| Wireless - Topix.net
An American public health expert will lecture Canadian doctors tomorrow about the hidden dangers of wireless radiation from their patients' cell phones, Wifi and other wireless consumer devices. "We've shown that men who keep phones in their pockets can have problems with infertility and possibly impotence ," said Dr. Devra Davis, PhD, President of Environmental Health Trust.
Tags: cell
phones
wireless
expert
Keryx pill for kidney disease patients cleared, but with safety warnings attached, shares fall
2014-09-05 22:05:57| Biotech - Topix.net
Keryx Biopharmaceuticals shares fell Friday as the company received U.S. approval for its pill to treat kidney disease complications but the clearance required unexpected safety warnings. The Food and Drug Administration approved the company's ferric citrate drug to treat patients on dialysis with hyperphosphatemia, or elevated levels of phosphates, which can increase the risk of heart disease, bone density problems and death.
Tags: fall
safety
attached
disease
Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent FF-10501' For FUJIFILM In Patients With Advanced Hematologic Malignancies
2014-09-03 11:37:54| drugdiscoveryonline Home Page
Boston Strategics Corporation (BSC), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has begun a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS)
Tags: with
advanced
corporation
agent
Sites : [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] next »